Name: Idarubicin Hydrochloride
Price: 259.00 USD

- Overview
  - Idarubicin Hydrochloride is the hydrochloride salt of Idarubicin, an anthracycline antibiotic and daunomycin analog with antimicrobial and anti-cancer antileukemic properties. It is a Topoisomerase II inhibitor, interfering with DNA replication and RNA transcription. The compound was developed by Johnson & Johnson. Idarubicin is metabolished into Idarubicinol (a 13-dihydro derivative) which is more stable than the parent form and just as active in in vitro models. The product is used in apoptosis research. Idarubicin Hydrochloride is soluble in DMSO.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Idarubicin has a higher DNA binding capacity and greater cytotoxicity than daunorubicin. It is a Topoisomerase II inhibitor, specifically the subunits GyrA and GyrB. It acts by stabilizing enzyme-DNA complexes wherein DNA strands are cut and covalently linked to the protein. The antineoplastic mechanism is mainly attributed to its DNA intercalating ability and its inhibition of Topo II impairs cellular DNA replication.
- Properties
  - CAS Number
    
    57852-57-0
    
    Molecular Formula
    
    C26H27NO9 · HCl
    
    Molecular Weight
    
    533.95
    
    Appearance
    
    Orange crystalline powder
    
    Solubility
    
    Soluble in DMSO
    
    Other Properties
    
    Source: Synthetic
    
    Storage
    
    2-8°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Idarubicin has activity against bacteria including Gram-positive cocci (MRSA, S. epidermidis) and yeasts.
    
    Cancer Applications: The effect of Idarubicin and idarubicinol on multicellular spheroids, a model that mimics the microregions of solid tumors, to examine in vitro cytotoxicity on MCF-7 breast cancer cells. Authors found Idarubicin and Idrubicinol have significant cytotoxic activity against multicellular spheroids with an IC50 of 7.9 ng/ml (Orlandi et al, 2005).